IRIS
CANTONETTI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 34.147
AS - Asia 3.823
EU - Europa 3.627
SA - Sud America 514
Continente sconosciuto - Info sul continente non disponibili 322
AF - Africa 65
OC - Oceania 11
Totale 42.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.918
SG - Singapore 1.707
CN - Cina 902
DE - Germania 850
IT - Italia 525
RU - Federazione Russa 466
BR - Brasile 430
UA - Ucraina 430
HK - Hong Kong 391
IE - Irlanda 338
VN - Vietnam 306
GB - Regno Unito 269
FR - Francia 240
CA - Canada 169
FI - Finlandia 155
KR - Corea 119
SE - Svezia 119
BD - Bangladesh 107
JP - Giappone 84
PL - Polonia 64
IN - India 43
MX - Messico 39
AR - Argentina 33
AT - Austria 30
NL - Olanda 30
BE - Belgio 28
ID - Indonesia 21
ZA - Sudafrica 21
IQ - Iraq 20
ES - Italia 19
KE - Kenya 18
CZ - Repubblica Ceca 15
TR - Turchia 15
EC - Ecuador 14
UZ - Uzbekistan 14
PH - Filippine 13
CH - Svizzera 11
AU - Australia 10
EU - Europa 10
TH - Thailandia 10
IL - Israele 9
JM - Giamaica 9
RO - Romania 9
CO - Colombia 8
PK - Pakistan 8
SA - Arabia Saudita 8
CL - Cile 7
VE - Venezuela 7
EG - Egitto 5
MA - Marocco 5
PY - Paraguay 5
TN - Tunisia 5
TW - Taiwan 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
KG - Kirghizistan 4
NO - Norvegia 4
PE - Perù 4
BG - Bulgaria 3
CR - Costa Rica 3
DZ - Algeria 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
LT - Lituania 3
MY - Malesia 3
AM - Armenia 2
BB - Barbados 2
BW - Botswana 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MK - Macedonia 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
SN - Senegal 2
TG - Togo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
DK - Danimarca 1
EE - Estonia 1
HT - Haiti 1
KH - Cambogia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
Totale 42.195
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.266
Wilmington 8.717
Houston 7.680
Singapore 885
Ann Arbor 810
Fairfield 770
Ashburn 614
Chandler 585
San Jose 419
Jacksonville 394
Hong Kong 388
Beijing 363
Seattle 343
New York 334
Dublin 324
Cambridge 279
Medford 238
Dearborn 198
Council Bluffs 182
Munich 172
Rome 166
Santa Clara 154
Los Angeles 125
Lawrence 114
Mcallen 111
Montréal 110
Ho Chi Minh City 99
The Dalles 98
Buffalo 81
Moscow 80
Lauterbourg 77
Zhengzhou 73
Tokyo 70
Hanoi 68
Mülheim 68
Dallas 61
Helsinki 60
Milan 54
Menlo Park 52
São Paulo 46
San Diego 43
Kraków 40
Shanghai 36
Hefei 34
Phoenix 33
Chicago 32
Guangzhou 29
Orem 29
London 28
Atlanta 27
Nuremberg 27
Brooklyn 26
University Park 23
Norwalk 21
Brussels 20
Mountain View 20
North Bergen 20
Saint Petersburg 20
Frankfurt am Main 19
Nanjing 19
Redondo Beach 18
Toronto 17
Warsaw 17
Montreal 16
Redwood City 16
Stockholm 16
Da Nang 15
Creede 14
Palo Alto 14
Seoul 14
Falls Church 13
Haiphong 13
Kunming 13
Naples 13
Rio de Janeiro 13
Center 12
Jakarta 12
Johannesburg 12
Meru 12
San Francisco 12
Amsterdam 11
Belo Horizonte 11
Boardman 11
Brno 11
Engelhard 11
Nürnberg 11
Bologna 10
Boston 10
Columbus 10
Denver 10
Springfield 10
Verona 10
Curitiba 9
Detroit 9
Dhaka 9
Vienna 9
Wuhan 9
Baghdad 8
Biên Hòa 8
Brasília 8
Totale 35.751
Salva come PNG Salva come JPEG
Nome #
Awake thoracoscopic biopsy of anterior mediastinal masses 880
Psoriasiform sarcoidosis: an unusual variety 713
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 586
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 518
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 516
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 495
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 490
Treatment of multiple myeloma: A randomized study of three different regimens 481
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial 479
Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol 479
Il trattamento chirurgico delle rinosinusiti nei pazienti oncoematologici: confronto tra procedure 471
Non-Hodgkin lymphomas of the central nervous system 469
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 465
Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients 464
Comprehensive analysis of PTEN status in Sezary syndrome 462
Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study 460
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 458
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 456
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients 456
Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma 454
WILL MOLECULAR-BIOLOGY CONTRIBUTE TO REFINE PROGNOSIS AND TO SELECT TREATMENT 450
SEQUENTIAL THERAPY WITH VAPLD AND BORTEZOMIB AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSION BEFORE STEM CELL MOBILIZATION 446
FISH analysis for CML monitoring? 445
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 445
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 443
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 442
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 441
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 441
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 436
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 436
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 435
Peripheral polyneuropathy during treatment with alpha-2 interferon 435
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 433
Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 431
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 428
Multiple skin tumors in long-term treatment with hydroxyurea 427
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia 422
Biological and clinical advances in multiple myeloma: A review 422
TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE 421
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 418
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. 416
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 416
Menstrual function in patients undergoing chemotherapy for Hodgkin's disease 416
Allogeneic stem cell transplantation for patients with advanced primary cutaneous T-cell lymphoma 414
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group 413
Reduced intensity allogeneic transplantation in primary cutaneous t-cell lymphomas. 412
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 411
Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma 409
PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE 408
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias 407
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: An update 406
EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY 406
EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986 405
Bone marrow processing with a gravity sedimentation technique: experience of 13 cases 404
Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia 403
CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE 403
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 402
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients 402
INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 400
Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis 396
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions 395
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment 394
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 393
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 393
CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 392
KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML 390
Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study 389
Chemotherapy in cutaneous T-cell lymphoma 388
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients 384
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 383
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients 383
Monitoring treatment and survbival in Cronic Myeloid Leukemia 382
Surgical management of rhinosinusitis in onco-hematological patients 381
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 381
Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy 379
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma 375
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease 370
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph 363
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 361
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION 360
Reduced-intensity conditioning combined with standard GvHD prophylaxis is tolerable and highly effective for patients with primary cutaneous T-cell lymphomas undergoing allogeneic transplantation in advanced disease stage. 360
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 350
Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT 348
[Current aspects of treatment of multiple myeloma] 345
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 345
Granulomatous mycosis fungoides responsive to gemcitabine 337
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs 331
Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression 282
Recurrent Sweet's syndrome in a patient with multiple myeloma 243
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 241
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 209
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 201
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 201
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients 200
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance 194
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 193
Preliminary results of a counselling programme for fertility preservation in female cancer patients: the experience of the GEMME DORMIENTI network 189
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 188
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant 188
Hepatic follicular lymphoma in an old patient with Crohn’s disease: a rare case and review of the literature 187
Totale 39.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.011 0 107 20 76 30 99 44 42 76 87 55 375
2022/20231.581 167 150 77 160 131 349 180 79 137 10 112 29
2023/2024737 51 20 61 20 38 298 30 31 18 13 25 132
2024/20252.633 92 559 302 143 43 139 210 135 201 238 295 276
2025/20264.440 313 222 516 346 404 200 502 475 441 418 436 167
2026/2027457 219 238 0 0 0 0 0 0 0 0 0 0
Totale 42.509